High-efficacy immunotherapies should be first line in MS: early starters have less disability
By Michael Woodhead
24 Mar 2020
Better long-term disability outcomes in MS patients who are ‘early starters’ on high-efficacy therapies show that it is time to think the traditional escalation approach, Australian neurologists say. Patients who started induction therapy within two years of disease onset had an average of one step difference in disability (Expanded Disability Status Scale, EDSS score) compared ...